Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

This study has been completed.
Information provided by:
Stanford University Identifier:
First received: May 18, 2007
Last updated: May 19, 2011
Last verified: May 2011
The purpose of the study is to conduct a phase I study of adoptive immunotherapy with autologous, ex-vivo expanded cytokine-induced killer (CIK) cells to reduce the relapse rate in autologous stem cell transplant patients with high-risk hematologic malignancies.

Condition Intervention Phase
Multiple Myeloma
Drug: CIK cells
Drug: busulfan
Drug: etoposide
Drug: bcnu
Drug: cyclophosphamide
Drug: gemcitabine
Drug: vinorelbine
Drug: melphalan
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Phase I/II Study of Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for the Treatment of High-risk Hematologic Malignancies

Resource links provided by NLM:

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • To document the toxicities of infusion of autologous CIK cells [ Time Frame: Day 42 post autologous stem cell transplant ] [ Designated as safety issue: Yes ]
  • Measure freedom from progression (FFP) [ Time Frame: 1 and 2 years post-transplant ] [ Designated as safety issue: No ]
  • Measure event free survival [ Time Frame: 1 and 2 years post-transplant ] [ Designated as safety issue: No ]
  • Measure overall survival [ Time Frame: 1 and 2 years post-transplant ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Measure disease response [ Time Frame: at day 40-60, day 90, day 180, and yearly ] [ Designated as safety issue: No ]

Enrollment: 22
Study Start Date: May 2006
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: CIK cells
    2x10e8 cells/kg
    Other Name: autologous cytokine-induced killer cells
    Drug: busulfan
    1 mg/kg
    Other Names:
    • Myleran
    • Busulfex IV
    Drug: etoposide
    60 mg/kg
    Other Names:
    • Eposin
    • Etopophos
    • Vepesid
    • VP-16
    Drug: bcnu
    15 mg/kg
    Other Name: Carmustine
    Drug: cyclophosphamide
    100 mg/kg
    Other Names:
    • Endoxan
    • Cytoxan
    • Neosar
    • Procytox
    • Revimmune
    • cytophosphane
    Drug: gemcitabine
    1250 mg/m2
    Other Name: Gemzar
    Drug: vinorelbine
    30 mg/m2
    Other Name: Navelbine
    Drug: melphalan
    200 mg/m2
    Other Names:
    • Alkeran
    • Melphalan hydrochloride
Detailed Description:
Disease relapse remains the major cause of treatment failure in autologous stem cell transplantation for patients with high-risk disease. Relapse after autologous transplant is in part due to the persistence of residual cancer cells. Cellular immunotherapy using activated autologous effector cells to recognize and kill tumor targets in a minimal disease state after transplant is a strategy being explored to reduce relapse and improve survival. We hypothesize that cytokine-induced killer (CIK) cell-based immunotherapy can reduce the relapse rate after high-risk autologous stem cell transplantation by treating post-transplant minimal residual disease.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients between 18 and 75 years of age, inclusive candidates for standard autologous SCT who are at high risk for relapse:

    • Acute myelogenous leukemia (AML), high risk, in CR1 or beyond without a donor (CR1 defined as: normal bone marrow morphology, resolution of any previously abnormal karyotype, neutrophils > 1000/ul, platelets > 100,000/ul, independence from red cell transfusion, no evidence extramedullary leukemia)
    • Hodgkin's lymphoma relapsed or refractory, with the presence of >= 1 adverse risk factor (Adverse risk factors are defined as stage IV involvement of the lung or bone marrow, constitutional symptoms, and the presence of more than minimal residual disease before the preparatory regimen)
    • Multiple myeloma with high risk features with only single autologous transplant option. High risk features defined as IgA myeloma, B2M > 2.5 mg/ml with normal kidney function, complex karyotypes or isolated chromosome 13 abnormalities, standard-dose therapy > 12 months, or inability to achieve at least 50% reduction of plasma cells in the bone marrow or 50% reduction in the paraprotein concentration after initial induction chemotherapy prior to transplant.
  • Patients must have ECOG performance status < 2
  • Patients must have adequate renal function with a serum creatinine of < 2 mg/dl or creatinine clearance > 50 ml/min.
  • Patients must have adequate liver function with a total bilirubin < 2 mg/dl or transaminases < 3 times the upper limit of normal.
  • Patients must have negative antibody serology for human immunodeficiency virus (HIV1 and 2)
  • Adult women and minorities will be included. Patients with childbearing potential must use effective contraception.
  • Patients must sign informed consent prior to initiation of any study-related treatments.

Exclusion Criteria:

  • ECOG performance status > 2
  • LVEF < 45%
  • Pulmonary diffusion capacity < 50% predicted
  • Total bilirubin > 2 mg/dl
  • Creatinine > 2 mg/dl
  • Pregnancy
  • Patients positive for HIV
  • Patients with engraftment failure at day 42 post transplant defined as failure to achieve a granulocyte count > 500/ul on 3 successive daily determinations and an unsupported platelet count of >= 50,000/ul by day 42
  • Patients with active, uncontrolled infection that is expected to continue beyond day 42-63.
  • Patients who fail to collect sufficient quantities of stem cells (> 1.6 x 10^9 cells) during apheresis to support CIK cell expansion cultures.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00477035

United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Principal Investigator: Sally Arai Stanford University
  More Information

Responsible Party: Sally Arai, Stanford University School of Medicine Identifier: NCT00477035     History of Changes
Other Study ID Numbers: BMT173  95889  BMT173 
Study First Received: May 18, 2007
Last Updated: May 19, 2011
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists
Antimetabolites, Antineoplastic processed this record on December 02, 2016